Discovery of Benzofuran-2-Carboxylic Acid Derivatives as Potent PTPRO Inhibitors with Oral Efficacy for Treatment of Inflammatory Bowel Disease
= 0.16 μM) and superior in vivo efficacy accompanied by an improved safety profile. This work establishes benzofuran-2-carboxylic acid derivatives as promising IBD therapeutics, providing a pharmacological tool for phosphatase-targeted immunomodulation.
Authors
- Hongyun Zhao (ORCID: https://orcid.org/0000-0002-1251-3888)
- Huirui Wang (ORCID: https://orcid.org/0009-0005-1907-6448)
- Xuben Hou (ORCID: https://orcid.org/0000-0002-8346-9001)
- X.C. Li (ORCID: https://orcid.org/0000-0002-5981-2762)
- Jintong Du
- Junxin Xue (ORCID: https://orcid.org/0000-0002-1983-4000)
- Zhongcheng Zhao
- Xiao Liang (ORCID: https://orcid.org/0000-0002-8159-161X)
- Xinying Yang (ORCID: https://orcid.org/0009-0005-9427-5033)
- H Y Fang
- Ting Dong
Institutions
- Academy of Medical Sciences (GB)
- Shandong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- Peking Union Medical College Hospital (CN)
- Shandong Tumor Hospital (CN)
- Institute of Medicinal Plant Development (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00259
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.00